Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Vogel, Daphne Y S ^a   Vereyken, Elly J F ^a   Glim, Judith E ^a   Heijnen, Priscilla D A M ^a   Moeton, Martina ^a   van der Valk, Paul ^a   Amor, Sandra ^a,b   Teunissen, Charlotte E ^a   van Horssen, Jack ^a   Dijkstra, Christine D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CD40; Macrophages; Mannose receptor; Multiple sclerosis

Indexed keywords

CD163 ANTIGEN; CD32 ANTIGEN; CD40 ANTIGEN; CD64 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MANNOSE RECEPTOR;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MICROGLIA; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; WHITE MATTER;

ADULT; AGED; ANTIGENS, CD40; BRAIN; CELLS, CULTURED; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 84874446407     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-35     Document Type: Article

References (66)

1. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002, 104:182-191. 10.1016/S0303-8467(02)00036-7, 12127652.
2. Van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000, 26:2-10. 10.1046/j.1365-2990.2000.00217.x, 10736062.
3. Lassmann H. Pathology of Multiple Sclerosis, McAlpine's MS 1998, London: Churchill Livingstone, 3.
4. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009, 29:13435-13444. 10.1523/JNEUROSCI.3257-09.2009, 2788152, 19864556.
5. Abdul-Majid K-B, Stefferl A, Bourquin C, Lassmann H, Linington C, Olsson T, Kleinau S, Harris RA. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand J Immunol 2002, 55:70-81. 10.1046/j.1365-3083.2002.01024.x, 11841694.
6. Sarchielli P, Greco L, Floridi A, Floridi A, Gallai V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 2003, 60:1082-1088.
7. Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Brück W. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 2000, 29:366-375. 10.1002/(SICI)1098-1136(20000215)29:4<366::AID-GLIA7>3.0.CO;2-Y, 10652446.
8. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002, 1:232-241. 10.1016/S1474-4422(02)00102-3, 12849456.
9. Conrad DJ, Kuhn H, Mulkins M, Highland E, Sigal E. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci USA 1992, 89:217-221. 10.1073/pnas.89.1.217, 48207, 1729692.
10. Hendriks JJA, Teunissen CE, De Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Brain Res Rev 2005, 48:185-195. 10.1016/j.brainresrev.2004.12.008, 15850657.
11. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988, 23:339-346. 10.1002/ana.410230405, 3132891.
12. Huitinga I, Van Rooijen N, De Groot CJ, Uitdehaag BM, Dijkstra CD. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 1990, 172:1025-1033. 10.1084/jem.172.4.1025, 2188611, 2145387.
13. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hövelmeyer N, Waisman A, Rülicke T, Prinz M, Priller J, Becher B, Aguzzi A. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005, 11:146-152. 10.1038/nm1177, 15665833.
14. Tanaka T, Ueno M, Yamashita T. Engulfment of axon debris by microglia requires p38 MAPK activity. J Biol Chem 2009, 284:21626-21636. 10.1074/jbc.M109.005603, 2755886, 19531468.
15. Baer AS, Syed YA, Kang SU, Mitteregger D, Vig R, Ffrench-Constant C, Franklin RJM, Altmann F, Lubec G, Kotter MR. Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain 2009, 132:465-481. 2640211, 19208690.
16. Kotter MR, Li W-W, Zhao C, Franklin RJM. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 2006, 26:328-332. 10.1523/JNEUROSCI.2615-05.2006, 16399703.
17. Kotter MR, Zhao C, Van Rooijen N, Franklin RJM. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005, 18:166-175. 10.1016/j.nbd.2004.09.019, 15649707.
18. Larsen PH, Wells JE, Stallcup WB, Opdenakker G, Yong VW. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003, 23:11127-11135.
19. Teunissen CE, Dijkstra CD, Jasperse B, Barkhof F, Vanderstichele H, Vanmechelen E, Polman CH, Bö L. Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. Neuropathol Appl Neurobiol 2006, 32:318-331. 10.1111/j.1365-2990.2006.00730.x, 16640650.
20. Yin Y, Henzl MT, Lorber B, Nakazawa T, Thomas TT, Jiang F, Langer R, Benowitz LI. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci 2006, 9:843-852. 10.1038/nn1701, 16699509.
21. Liu X, Hawkes E, Ishimaru T, Tran T, Sretavan DW. EphB3: an endogenous mediator of adult axonal plasticity and regrowth after CNS injury. J Neurosci 2006, 26:3087-3101. 10.1523/JNEUROSCI.4797-05.2006, 16554460.
22. Bouhy D, Malgrange B, Multon S, Poirrier A-L, Scholtes F, Schoenen J, Franzen R. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages. FASEB J 2006, 20:1239-1241. 10.1096/fj.05-4382fje, 16636109.
23. Boven LA, Van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004, 122:359-369. 10.1309/BG5VA8JRDQH1M7HN, 15362365.
24. Van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort HL. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ 1972, 46:845-852. 2480884, 4538544.
25. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992, 176:287-292. 10.1084/jem.176.1.287, 2119288, 1613462.
26. Biondi A, Rossing TH, Bennett J, Todd RF. Surface membrane heterogeneity among human mononuclear phagocytes. J Immunol 1984, 132:1237-1243.
27. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686. 10.1016/j.it.2004.09.015, 15530839.
28. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212. 10.1189/jlb.0602325, 12554797.
29. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006, 80:1298-1307. 10.1189/jlb.0406249, 2642590, 16905575.
30. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969. 10.1038/nri2448, 2724991, 19029990.
31. Parsa R, Andresen P, Gillett A, Mia S, Zhang X-M, Mayans S, Holmberg D, Harris RA. Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice. Diabetes 2012, 61:2881-2892. 10.2337/db11-1635, 22745325.
32. Verreck FAW, De Boer T, Langenberg DML, Van der Zanden L, Ottenhoff THM. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol 2006, 79:285-293.
33. Verreck FAW, De Boer T, Langenberg DML, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Kolk A, De Waal-Malefyt R, Ottenhoff THM. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004, 101:4560-4565. 10.1073/pnas.0400983101, 384786, 15070757.
34. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, Zlabinger GJ, Stulnig TM. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 2007, 31:1420-1428.
35. Ambarus CA, Krausz S, Van Eijk M, Hamann J, Radstake TRDJ, Reedquist KA, Tak PP, Baeten DLP. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 2012, 375:196-206. 10.1016/j.jim.2011.10.013, 22075274.
36. Durafourt BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, Guiot M-C, Bar-Or A, Antel JP. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 2012, 60:717-727. 10.1002/glia.22298, 22290798.
37. Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou C-L, Ransohoff RM, Charo IF. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 2010, 5:e13693. 10.1371/journal.pone.0013693, 2965160, 21060874.
38. Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, Aerts JM, Amor S, Nieuwenhuis EE, Laman JD. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 2006, 129:517-526.
39. Van Rossum D, Hilbert S, Strassenburg S, Hanisch U-K, Brück W. Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype. Glia 2008, 56:271-283. 10.1002/glia.20611, 18069669.
40. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, Van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997, 56:10-20. 10.1097/00005072-199701000-00002, 8990125.
41. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996, 93:2499-2504. 10.1073/pnas.93.6.2499, 39826, 8637903.
42. De Groot CJ, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, Van der Valk P. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001, 124:1635-1645. 10.1093/brain/124.8.1635, 11459754.
43. Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, Van der Valk P, De Vries HE. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 2008, 45:1729-1737. 10.1016/j.freeradbiomed.2008.09.023, 18930811.
44. Witte ME, Bø L, Rodenburg RJ, Belien JA, Musters R, Hazes T, Wintjes LT, Smeitink JA, Geurts JJG, De Vries HE, Van der Valk P, Van Horssen J. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009, 219:193-204. 10.1002/path.2582, 19591199.
45. Van Horssen J, Vos CMP, Admiraal L, Van Haastert ES, Montagne L, Van der Valk P, De Vries HE. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol Appl Neurobiol 2006, 32:585-593. 10.1111/j.1365-2990.2006.00766.x, 17083473.
46. Gratchev A, Kzhyshkowska J, Köthe K, Muller-Molinet I, Kannookadan S, Utikal J, Goerdt S. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 2006, 211:473-486. 10.1016/j.imbio.2006.05.017, 16920487.
47. Fabriek BO, Van Haastert ES, Galea I, Polfliet MMJ, Döpp ED, Van Den Heuvel MM, Van Den Berg TK, De Groot CJA, Van Der Valk P, Dijkstra CD. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005, 51:297-305. 10.1002/glia.20208, 15846794.
48. Fleetwood AJ, Dinh H, Cook AD, Hertzog PJ, Hamilton JA. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J Leukoc Biol 2009, 86:411-421. 10.1189/jlb.1108702, 19406830.
49. Becker S, Daniel EG. Antagonistic and additive effects of IL-4 and interferon-gamma on human monocytes and macrophages: effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol 1990, 129:351-362. 10.1016/0008-8749(90)90211-9, 2166625.
50. Porcheray F, Viaud S, Rimaniol A-C, Léone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005, 142:481-489. 1809537, 16297160.
51. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN. LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood 2005, 106:3114-3122. 10.1182/blood-2005-02-0759, 1895321, 16020513.
52. Chroneos Z, Shepherd VL. Differential regulation of the mannose and SP-A receptors on macrophages. Am J Physiol 1995, 269:L721-726.
53. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008, 131:288-303.
54. Ulvestad E, Williams K, Vedeler C, Antel J, Nyland H, Mørk S, Matre R. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 1994, 121:125-131. 10.1016/0022-510X(94)90340-9, 8158203.
55. Melief J, Koning N, Schuurman KG, Van De Garde MDB, Smolders J, Hoek RM, Van Eijk M, Hamann J, Huitinga I. Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia 2012, 60:1506-1517. 10.1002/glia.22370, 22740309.
56. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, Hafler DA. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995, 182:1985-1996. 10.1084/jem.182.6.1985, 2192240, 7500044.
57. Togo T, Akiyama H, Kondo H, Ikeda K, Kato M, Iseki E, Kosaka K. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res 2000, 885:117-121. 10.1016/S0006-8993(00)02984-X, 11121537.
58. Laman JD, Van Meurs M, Schellekens MM, De Boer M, Melchers B, Massacesi L, Lassmann H, Claassen E, Hart BA. Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). J Neuroimmunol 1998, 86:30-45. 10.1016/S0165-5728(98)00024-1, 9655470.
59. Perry VH, Nicoll JAR, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6:193-201. 10.1038/nrneurol.2010.17, 20234358.
60. Breij ECW, Brink BP, Veerhuis R, Van den Berg C, Vloet R, Yan R, Dijkstra CD, Van der Valk P, Bö L. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008, 63:16-25. 10.1002/ana.21311, 18232012.
61. Becher B, Durell BG, Miga AV, Hickey WF, Noelle RJ. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med 2001, 193:967-974. 10.1084/jem.193.8.967, 2193406, 11304557.
62. Benveniste EN, Nguyen VT, Wesemann DR. Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav Immun 2004, 18:7-12. 10.1016/j.bbi.2003.09.001, 14651941.
63. Laman JD, t Hart BA, Brok H, van Meurs M, Schellekens MM, Kasran A, Boon L, Bauer J, de Boer M, Ceuppens J. Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur J Immunol 2002, 32:2218-2228. 10.1002/1521-4141(200208)32:8<2218::AID-IMMU2218>3.0.CO;2-0, 12209634.
64. Boon L, Brok HP, Bauer J, Ortiz-Buijsse A, Schellekens MM, Ramdien-Murli S, Blezer E, Van Meurs M, Ceuppens J, De Boer M, t Hart BA, Laman JD. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 2001, 167:2942-2949.
65. t Hart BA, Hintzen RQ, Laman JD. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis 2008, 5:38-52. 10.1159/000109937, 18075274.
66. Zhang Z, Zhang Z-Y, Schittenhelm J, Wu Y, Meyermann R, Schluesener HJ. Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. J Neuroimmunol 2011, 237:73-79. 10.1016/j.jneuroim.2011.06.006, 21737148.